Bita Asghari, OD, FAAO, FSLS, discusses diagnosing ocular surface inflammation, recognizing atypical keratitis, and knowing when to refer to a cornea specialist.
Publication|Articles|June 20, 2024
- June digital edition 2024
- Volume 16
- Issue 06
Utilizing the immune system to combat dry eye disease
Author(s)Walter O. Whitley OD, MBA, FAAO
Exploring strategies for effective management of a multifaceted condition.
Advertisement
Advertisement
Dry eye disease (DED) is a chronic and often progressive condition that can be a source of frustration for patients and clinicians.1 Finding the right combination of treatments that effectively alleviate symptoms can be demanding, and the chronic nature of the condition typically requires ongoing management to maintain ocular health and comfort.
Related to this article
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.
As artificial intelligence advances, so do VR devices.
Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.
The approval followed complete response letters tied to inspection and manufacturing issues.
What to take away on PBM, hormonal eye health, and GLP-1 receptor agonists from this year’s meeting.
Advertisement
Advertisement